medigraphic.com
ISSN 2448-8909 (Print)

2018, Number 4

<< Back Next >>

Med Crit 2018; 32 (4)

Citicoline, should we continue to indicate it in ischemic CVD?

Echezuría MFE, Quijada MRJ

Language: Spanish
References: 30
Page: 232-236
PDF size: 131.56 Kb.


ABSTRACT

Ischemic cerebrovascular disease (CVD) is a medical condition that, according to its extension, implies significant disability for the patient, as well as high costs for its acute and chronic treatment, as well in the management of disability, with high incidence and worldwide prevalence, from the physiopathological point of view represents a catastrophe in brain functioning that involves structural and functional damage. Multiple strategies have been developed for the management of this pathology, currently the gold standard for its management is the rt-PA, however, due to its characteristics, and few patients have access to it, because it various pharmacological strategies have been developed. Citicoline has been used for years, nevertheless generates controversies since its usefulness, demonstrated in experimental studies, has not been reproduced in clinical practice but some studies suggest that it could worsen the patient’s prognosis, which would justify the abandonment of its use in the treatment of ischemic CVD (ictus), for this reason we offer this review of the subject in order to provide tools to clarify this controversy.


REFERENCES

  1. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet. 2014;383(9913):245-254.

  2. Mukherjee D, Patil G. Epidemiology and the global burden of stroke. World Neurosurg. 2011;76(Suppl. 6):S85-90.

  3. Mackay J, Mensah G; World Health Organization. The atlas of heart disease and stroke. Brighton: Myriad Editions Ltd.; 2004.

  4. Alvarez-Sabín J, Santamarina E, Maisterra O, Jacas C, Molina C, Quintana M. Long-term treatment with citicoline prevents cognitive decline and predicts a better quality of life after a first ischemic stroke. Int J Mol Sci. 2016;17:390.

  5. Labiche LA, Grotta JC. Clinical trials for cytoprotection in stroke. NeuroRx. 2004;1:46-70.

  6. Adams H, Adams R, Del Zoppo G, Goldstein LB; Stroke Council of the American Heart Association; American Stroke Association. Stroke Council of the American Heart Association; American Stroke Association. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update. Stroke. 2005;36(4):916-923.

  7. Overgaard K. The effects of citicoline on acute ischemic stroke: a review. J Stroke Cerebrovasc Dis. 2014;23(7):1764-1769.

  8. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol. 2006;28(Suppl B):1-56.

  9. Ulus IH, Wurtman RJ, Mauron C, Blusztajn JK. Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum. Brain Res. 1989;484(1-2):217-227.

  10. Manaka S, Sano K, Fuchinoue T, Sekino H. Mechanism of action CDP-choline in parkinsonism. Experientia. 1974;30(2):179-180.

  11. Horrocks LA, Dorman RV, Dabrowiecki Z, Goracci G, Porcellati G. CDPcholine and CDP ethanolamine prevent the release of free fatty acids during brain ischemia. Prog Lipid Res. 1981;20:531-534.

  12. Horrocks LA, Dorman RV, Dabrowiecki ZM. Therapeutic agents for preventing phospholipid degradation and free fattyacid proliferation. United States Patent. 1981;4:378-386.

  13. Adibhatla M, Hatcher F. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002;70(2):133-139.

  14. Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J Neurol Sci. 2007;257(1-2):264-269.

  15. Galletti P, De Rosa M, Cotticelli MG, Morana A, Vaccaro R, Zappia V. Biochemical rationale for the use of CDPcholine in traumatic brain injury: pharmacokinetics of the orally administered drug. J Neurol Sci. 1991;103 Suppl.: S19-25.

  16. Galletti P, De Rosa M, Nappi MA, Pontoni G, del Piano L, Salluzzo A, Zappia V. Transport and metabolism of double labelled CDPcholine in mammalian tissues. Biochem Pharmacol. 1985;34(23):4121-4130.

  17. Cotroneo AM, Castagna A, Putignano S, Lacava R, Fantò F, Monteleone F, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013; 8: 131-137.

  18. Gutiérrez-Fernández M, Leciñana MA, Rodríguez-Frutos B, Ramos-Cejudo J, Roda JM, Díez-Tejedor E. CDP-choline at high doses is as effective as i.v. thrombolysis. Neurol Res. 2012;34(7):649-956.

  19. Le Poncin-Lafitte M, Duterte D, Lageron A, Rapin JR. CDP choline et accident cérébral expérimental d’origine vasculaire. Agressologie. 1986;27(5):413-416.

  20. Watanabe S, Kono S, Nakashima Y, Mitsunobu K, Otsuki S. Effects of various cerebral metabolic activators on glucose metabolism of brain. Folia Psychiatr Neurol Jpn. 1975;29:67-76.

  21. Lee HJ, Kang JS, Kim YI. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Clin Neurol. 2009;5(1):33-38.

  22. Giralt D, García-Bonilla L, et al Selecting the optimal dose of citicoline treatment in Danimal models of focal cerebral ischemia through a meta-analysis. Cerebrovasc Dis. 2010;29(Suppl. 2):165.

  23. Leon-Jimenez C, Chiquete E, Cantu C, Miramontes-Saldana MJ, Andrade-Ramos MA, Ruiz-Sandoval JL. Citicoline for acute ischemic stroke in mexican hospitals: a retrospective postmarketing analysis. Methods Find Exp Clin Pharmacol. 2010;32(5):325-330.

  24. Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. 1999;30(12):2592-2597.

  25. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE; Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 2001;57(9):1595-1602.

  26. Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, et al. Effect of citicoline on ischemic lesions as measured by diffusion weighted magnetic resonance imaging. Ann Neurol. 2000;48(5):713-722.

  27. Warach SJ, Sabounjian LA. ECCO 2000 study of citicoline for treatment of acute ischemic stroke: effects on infarct volumes measured by MRI. Stroke. 2000;31:283.

  28. Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380(9839):349-357.

  29. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947.

  30. Powers WJ, Rabinstein CA, Teri Ackerson VC, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2018;49:e46-e99.




2020     |     www.medigraphic.com